Affordable Prescriptions for Patients Act
Latest Action
Held at the desk.
Official Summary
Affordable Prescriptions for Patients Act This bill limits in certain instances the number of patents that the manufacturer of a biologic drug can assert in a lawsuit against a company seeking to sell a biosimilar version of that drug. (A biologic drug is produced through natural processes or isolated from natural sources. A biosimilar version is substantially similar to the original biologic, which is the reference product, and is often marketed as a less expensive alternative.) The bill's provisions apply to an existing framework that gives the biosimilar manufacturer an abbreviated path to Food and Drug Administration approval to sell the biosimilar. Specifically, if the biosimilar manufacturer completes certain actions under the framework, such as sharing certain information about its product with the reference product manufacturer, the bill limits the number of certain patents that the reference product manufacturer may assert in a lawsuit, such as patents that were filed more than four years after the reference product received market approval. The limit shall not apply to patents claiming certain methods for using the biologic drug. The court in which the infringement lawsuit is filed may increase the limit if justice so requires or if there is good cause for the increase.
GovScope Watchdog™
AI Government Intelligence™The Affordable Prescriptions for Patients Act aims to limit the number of patents that manufacturers of biologic drugs can assert in lawsuits against companies seeking to market biosimilar versions of those drugs. This limitation applies when the biosimilar manufacturer follows certain procedural steps under the existing FDA approval framework, such as sharing product information with the original biologic manufacturer. The bill restricts assertion of patents filed more than four years after the original biologic's market approval, except for patents related to specific methods of using the biologic drug. Courts may increase the patent assertion limit if justified by circumstances.
This bill seeks to streamline patent litigation related to biosimilar drugs by capping the number of patents that can be asserted, potentially facilitating market entry of lower-cost biosimilars while preserving certain patent protections.
- Limits the number of patents a biologic drug manufacturer can assert in lawsuits against biosimilar manufacturers under defined conditions.
- Applies to patents filed more than four years after the original biologic drug received market approval, with exceptions for method-of-use patents.
- Allows courts discretion to increase the patent assertion limit if justice or good cause is demonstrated.
['Biosimilar drug manufacturers seeking to enter the market with lower-cost alternatives', 'Patients who may gain access to more affordable biologic treatments', 'Healthcare providers and payers interested in cost-effective treatment options']
['Implementation challenges in determining which patents are subject to limitation and ensuring compliance with information-sharing requirements', 'Judicial discretion in increasing patent assertion limits could lead to variability in enforcement', 'Potential legal and administrative costs associated with patent litigation under the new framework']
The bill addresses ongoing policy discussions about balancing patent protections for biologic drug innovators with the need to promote competition and reduce drug costs through biosimilars. It builds on an existing FDA regulatory framework that facilitates biosimilar approval and reflects legislative efforts to clarify patent litigation procedures in this sector. The bill is currently in process and was last noted as 'Held at the desk' as of July 21, 2026.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential acceleration of biosimilar market entry due to reduced patent litigation barriers', 'Possible increased legal disputes over court decisions to raise patent assertion limits', 'Enhanced access to lower-cost biologic treatments for patients and healthcare systems']
The bill's effectiveness depends on clear definitions and consistent application of patent assertion limits and procedural requirements. Oversight of judicial discretion and compliance with information-sharing provisions will be important to ensure transparency and fairness in patent litigation involving biologic and biosimilar drugs. The absence of full bill text limits detailed analysis of specific enforcement mechanisms and funding.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.